logo
  

Lifecore Biomedical Falls On Approval Of Strategic Alternatives, Appointment Of CEO

Lifecore Biomedical, Inc. (LFCR) shares are falling more than 35 percent on Wednesday morning trade after the company announced approval for its review of strategic alternatives. The company also announced strategic updates related to its operations on a stand-alone basis. Further, the company named Paul Josephs as chief executive office to succeed James Hall on his retirement.

Currently, shares are at $4.71, down 34.49 percent from the previous close of $7.19 on a volume of 1,292,191.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

Jobless claims data was the highlight in this relatively light week for U.S. economics. In Europe, focus was on the U.K. economy where the Bank of England announced its latest policy decision and the first quarter GDP data were released. Find out the signals from the central bank and whether or not the UK economy exited a recession. In the Asia-Pacific, Australia's central bank delivered its latest policy verdict and China released trade figures.

View More Videos
Follow RTT